Erick has been leading Medical Affairs at PathAI for the last two years. One of his main focuses has been the market access and reimbursement strategy for novel and innovative diagnostics, where he works with internal teams on evidence generation requirements and external stakeholders on advancing coverage and reimbursement for AI-based diagnostics. Prior to joining PathAI, Erick served as Medical Director and Head of Medical Affairs for the Blue Cross Blue Shield Associations (BCBSAs) health technology assessment group, Evidence Street, as well as the BCBSA medical policy team. Since completing his pathology residence and molecular genetic pathology fellowship at UCLA, he has engaged with healthcare technology evaluators and payers to facilitate coverage and reimbursement for new healthcare technologies such as next-generation sequencing and novel diagnostics.
AI/ML-related healthcare products/services have begun changing the healthcare landscape. Watershed events in AI diagnostics include recent FDA approvals in imaging and data integration and guidance for Software as a Medical Device. What role will AI/ML play and what should criteria be for reimbursement as healthcare pivots to value-base models?